Abstract

To observe the clinical efficacy of budesonide/formoterol inhalation aerosol in conjunction with doxofylline in treating individuals with stable chronic obstructive pulmonary disease. Our study enrolled a total of 90 patients with stable chronic obstructive pulmonary disease, who were admitted to our hospital from September 2019 to June 2021. These participants were allocated randomly into two groups; the control group and the observation group, comprising 45 patients in each group. Doxofylline was administered to the control group, while the observation group received additional treatment of budesonide/formoterol inhalation aerosol alongside doxofylline. The duration of treatment for both groups was set at 6 mo. The clinical efficacy was determined by evaluating the improvement of clinical symptoms, along with the assessment of pulmonary function, and the measurement of serum levels of interleukin-8, transforming growth factor-beta 1, and tumor necrosis factor-alpha. With a total effective rate of 99.33 %, the observation group outperformed the control group, which achieved a rate of 73.33 %. The baseline measurements of pulmonary function indicators, as well as interleukin-8, transforming growth factor-beta 1, and tumor necrosis factor-alpha levels, showed no remarkable distinctions between the two groups. However, post-treatment evaluations revealed noteworthy improvements in the observation group's forced expiratory volume in the first second/forced vital capacity values compared to their respective pre-treatment levels. These improvements were notably higher than those observed in the control group (p<0.05). Additionally, the observation group exhibited a more substantial decrease in interleukin-8, tumor necrosis factor-alpha, and transforming growth factor-beta 1 levels compared to the control group. Furthermore, no significant difference was observed in the incidence of adverse reactions between the two groups (p>0.05). Budesonide/formoterol inhalation aerosol in conjunction with doxofylline in treating individuals with stable chronic obstructive pulmonary disease significantly improves clinical symptoms, enhances pulmonary function, exhibits good anti-inflammatory effects, and has a good safety profile.